Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to assess the effect of forearm ischemia-reperfusion injury on sympathetic nerve activity. To determine whether reduced sympathetic responsiveness is a contributor to the protective effects of remote ischemic preconditioning. In addition it will assess whether pharmacologic inhibition of the sympathetic nervous system can ameliorate ischemia reperfusion injury induced endothelial dysfunction.
This is a randomized single blind study where subjects will be allocated to undergo one of the 4 protocols. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
This medication acts by reducing the activity of nerves believed to be involved in the conditioning process. The placebo pill, designed to have no effect, will be used as a comparison. Comprehensive tests will occur which include Microneurography, Endothelial function ,Blood Sampling, Temporary block of arm blood flow and Remote conditioning
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No conditioning + placebo | Experimental | Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests. |
|
| No conditioning + moxonidine | Experimental | Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement without conditioning tests. |
|
| Remote pre-conditioning + placebo | Experimental | Participants will be given placebo to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests. |
|
| Remote pre-conditioning + moxonidine | Experimental | Participants will be given moxonidine to take orally 20 minutes prior to the first endothelial function measurement with conditioning tests. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Moxonidine 0.2 MG | Drug | Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement. |
| Measure | Description | Time Frame |
|---|---|---|
| change in muscle sympathetic nerve activity | Muscle sympathetic nerve activity assessed by microneurography | 1 day |
| Measure | Description | Time Frame |
|---|---|---|
| Endothelial Function using the EndoPat2000 device | Endothelial Function testing involves the measurement of pulse amplitude from the tip of each index finger at rest and after a period of occlusion using an arm cuff that is manually inflated to a level above that of the participant's Blood Pressure (BP). | 2 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
50 healthy male volunteers (25 aged 18-30 years and 25 aged 60-75 years)
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Markus Schlaich, MD,FAHA,FESC | Royal Perth Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dobney Hypertension Centre | Perth | Australia |
Not provided
| ID | Term |
|---|---|
| D007511 | Ischemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C043482 | moxonidine |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| placebo | Other | Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement. |
|